A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.